+

WO2003104259A3 - PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF - Google Patents

PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF Download PDF

Info

Publication number
WO2003104259A3
WO2003104259A3 PCT/US2003/017641 US0317641W WO03104259A3 WO 2003104259 A3 WO2003104259 A3 WO 2003104259A3 US 0317641 W US0317641 W US 0317641W WO 03104259 A3 WO03104259 A3 WO 03104259A3
Authority
WO
WIPO (PCT)
Prior art keywords
hla
molecules
peptides presented
peptides
hls
Prior art date
Application number
PCT/US2003/017641
Other languages
French (fr)
Other versions
WO2003104259A2 (en
Inventor
Janine Bilsborough
Yi Zhang
Erwin Schultz
Christophe Panichelli
Der Bruggen Pierre Van
Thierry Boon-Falleur
Catia Traversari
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/164,121 external-priority patent/US20030228308A1/en
Priority claimed from US10/164,078 external-priority patent/US7041502B2/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Priority to AU2003249693A priority Critical patent/AU2003249693A1/en
Publication of WO2003104259A2 publication Critical patent/WO2003104259A2/en
Publication of WO2003104259A3 publication Critical patent/WO2003104259A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptides, previously identified as binding partners of HLA-B44, HLA-Cw3 and HLS-Cw16 have now been found to bind to HLA-B18 and HLA-Cw6 forming T cell epitopes. The therapeutic and diagnostic ramifications of this are the subjects of this invention, as are various products obtained in the course of the development of the invention.
PCT/US2003/017641 2002-06-05 2003-06-04 PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF WO2003104259A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003249693A AU2003249693A1 (en) 2002-06-05 2003-06-04 PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/164,121 2002-06-05
US10/164,121 US20030228308A1 (en) 2002-06-05 2002-06-05 Isolated peptides which bind to HLA-Cw6 molecules and uses thereof
US10/164,078 US7041502B2 (en) 2002-06-05 2002-06-05 Isolated peptides which bind to HLA-B18 molecules and uses thereof
US10/164,078 2002-06-05

Publications (2)

Publication Number Publication Date
WO2003104259A2 WO2003104259A2 (en) 2003-12-18
WO2003104259A3 true WO2003104259A3 (en) 2004-07-08

Family

ID=29738933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017641 WO2003104259A2 (en) 2002-06-05 2003-06-04 PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF

Country Status (2)

Country Link
AU (1) AU2003249693A1 (en)
WO (1) WO2003104259A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750395A (en) * 1993-08-06 1998-05-12 Cytel Corporation DNA encoding MAGE-1 C-terminal cytotoxic t lymphocyte immunogenic peptides
US6303756B1 (en) * 1998-07-27 2001-10-16 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US20030228325A1 (en) * 2002-06-05 2003-12-11 Janine Bilsborough Isolated peptides which bind to HLA-B18 molecules and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750395A (en) * 1993-08-06 1998-05-12 Cytel Corporation DNA encoding MAGE-1 C-terminal cytotoxic t lymphocyte immunogenic peptides
US6303756B1 (en) * 1998-07-27 2001-10-16 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US20030228325A1 (en) * 2002-06-05 2003-12-11 Janine Bilsborough Isolated peptides which bind to HLA-B18 molecules and uses thereof

Also Published As

Publication number Publication date
WO2003104259A2 (en) 2003-12-18
AU2003249693A8 (en) 2003-12-22
AU2003249693A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
MX2007008017A (en) Polypeptides that bind br3 and uses thereof.
MXPA05010830A (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2.
EA201100694A1 (en) ANTIBODY TO CD38 PERSON AND ITS APPLICATION
MX2007013626A (en) Antibodies directed against amyloid-beta peptide and methods using same.
MX2009012949A (en) Humanized antibodies which bind to aî² (1-42) globulomer and uses thereof.
DE602005026789D1 (en) LE
JO2828B1 (en) Anti-Hepcidin Antibodies and Uses Thereof
WO2004089396A3 (en) Anti-fungal peptidomimetics
WO2003057134A3 (en) Specific binding agents of human angiopoietin-2
WO2004067023A3 (en) Survivin-derived peptides and use thereof
EA200801509A1 (en) HUMAN MONOCLONAL ANTIBODIES TO PROTEINTHYROSINKINASE 7 (PTK7) AND METHODS OF APPLICATION OF ANTIBODIES AGAINST PTK7
EP2283868A3 (en) Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer
MX2009013824A (en) Antigen binding proteins that bind par-2.
EP1983002A3 (en) Tyrosine phosphorylation sites and antibodies specific for them
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
WO2005028497A3 (en) Receptor binding peptides derived from the sars s protein
WO2021262597A3 (en) Lair-1-binding agents and methods of use thereof
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
DE69931482D1 (en) ISOLATED PEPTIDES CORRESPOND TO THE AMINO ACID SEQUENCES OF NY-ESO-1 AND BIND MOLECULES AT MHC CLASS I AND MHC CLASS II, AND THEIR USES
MXPA05011085A (en) Compositions and methods relating to stop-1.
WO2004018619A3 (en) P53 binding t cell receptor molecules and uses thereof
WO2008036337A3 (en) Predicted phosphorylation sites
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2003076472A3 (en) Neoplasm specific antibodies and uses thereof
WO2003104259A3 (en) PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载